Skip to main content

ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

LOS ANGELES, Oct. 03, 2024 (GLOBE NEWSWIRE) — ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, announced its financial results for the second quarter and six-month period ending June 30, 2024. The company delivered a strong financial performance with notable revenue consistency, positive net income, and a robust increase in cash reserves.

Financial Highlights for Q2 2024:

  • Revenue: ViaDerma maintained steady revenues of $300,191 for the first half of 2024, compared to $300,230 for the same period in 2023, showing resilience in its sales despite challenging market conditions.
  • Net Income: The company achieved a net income of $54,008 for the six-month period, a significant improvement from the net loss of $75,576 reported during the same period in 2023. This turnaround reflects a positive shift in profitability, representing a 171.5% increase in earnings.
  • Cash Reserves: Cash and cash equivalents surged to $826,175 as of June 30, 2024, a remarkable 7,972% increase compared to $10,243 at the end of 2023. This growth is attributed to enhanced cash flow from operations and improved financial management.
  • Liabilities: The company reduced its total liabilities to $1,096,509, compared to $1,157,684 at the end of 2023, reflecting a 5.3% decrease in its debt burden.

The recent sale of 1 million units of its tetracycline-based topical antibiotic to Nigeria is not reflected in the financial results for Q2 2024. The first 500,000 units were shipped from the manufacturer in August 2024, with another 500,000 units scheduled for October 2024. The revenues from the August shipment will appear in the next quarterly report.

The report also highlighted ViaDerma’s continued progress in its operations, particularly with its lead product, Vitastem, an FDA-registered topical antibiotic that has gained significant market traction. This product continues to be met with strong customer acceptance and positive clinical outcomes, contributing to the company’s steady revenue stream.

ViaDerma is advancing its product pipeline with innovations in anti-aging skincare, pain management, hair-loss treatments, sexual wellness products and a CBD-based product targeting inflammation and conditions like nicotine addiction, fibromyalgia, and multiple sclerosis. The company is also strengthening its market presence by adopting a wholesale distribution model to boost sales and expand product availability in new regions, and exploring joint ventures with established pharmaceutical companies.

“We’re pleased with our strong Q2 results, which we believe marks the beginning of what we expect will lead to significantly higher growth for our Company,” said Dr. Christopher Otiko, President and CEO of ViaDerma.

About ViaDerma, Inc.
ViaDerma, Inc. (OTC Pink: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative transdermal drug delivery technology solutions to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit: https://viaderma.com

Any forecast of future performance is a “forward looking statement” under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

Contact information:
Investor Relations
Email: ir@viaderma.com
Phone: 310-734-6111

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.